65,437 trials
Keloid
Primary: The Primary Purpose of This Study Will be to Gain Preliminary Safety Experience With Apligraf in the Keloid Indication. The Number of Participants Experiencing AEs is…
Arterial Occlusive Disease · Peripheral Vascular Disease · Ischemia
Primary: Wound Healing (Change in Total Wound Area of All Ischemic Ulcers) — 5.75; 12.600; 15.766; 12.200 total wound area (cm^2) — p=0.35
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of…
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 2 + 1 Day, Day 15) — 1.35; 1.38; 1.38; 1.40 Liters
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) at End of Treatment (Week 12) — 1.44; 1.43 Liters
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment — 1.45; 1.39; 1.28 Liters
Pulmonary Disease, Chronic Obstructive · COPD · Lung Diseases, Obstructive
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment — 1.46; 1.46; 1.42; 1.28 Liters
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of…
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Each Treatment Period (Day 15) — 1.46; 1.26; 1.37 Liters
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85) — 1.48; 1.35 Liters
Anesthesia, General · Neuromuscular Blockade
Primary: Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9. — 1.4; 6.7; 1.6; 9.1 minutes
COPD
Primary: The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to Placebo — 3; 3; 2; 0…
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85 — 1.48; 1.48; 1.38; 1.31 Liters
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes to 11 Hours 45 Minutes Post-dose at the End of…
Adhesive Capsulitis
Primary: Range of Motion (ROM) of the Glenohumeral Joint — 261.95; 241.84 degree